HIV Infections Clinical Trial
— BUDDYOfficial title:
Bidirectional, Upbeat Communication and Differentiated, Distanced Care for Young People
NCT number | NCT04781400 |
Other study ID # | 448/2020 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | February 8, 2021 |
Est. completion date | May 13, 2022 |
Verified date | August 2022 |
Source | Desmond Tutu HIV Foundation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Sub Saharan Africa is home to only 12% of the population, but accounts for approximately 70% of the global burden of HIV infection and 84% of infections among young people aged 10-24 years. South Africa, which currently has the largest SARS-CoV-2 pandemic in SSA, also has the largest HIV epidemic globally. Access and service delivery barriers to engaging in HIV care have contributed to estimates that only 49% of adolescents (aged 10-19 years) entering care from 2005-2016 have initiated antiretroviral therapy (ART). In response to the SARS-CoV-2 pandemic the South African government has implemented national lock-down orders that we predict will further inhibit treatment engagement among young people. Research is needed to identify best practices for safely retaining young people living with HIV (YPLWH) in care during COVID-19.
Status | Completed |
Enrollment | 536 |
Est. completion date | May 13, 2022 |
Est. primary completion date | May 13, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 13 Years to 24 Years |
Eligibility | Inclusion Criteria: Young people living with HIV who meet all of the following criteria will be eligible for inclusion into this study: 1. Speak isiXhosa and or English, residing in the Khayelitsha /Mitchell's Plain area 2. 13-24 years (inclusive) 3. Willing and able to provide informed telephonic or in person consent 4. Initiated ART at one of two health facilities and are currently in HIV care (i.e. received ART and had a viral load measurement in the past six months) 5. Regular access to a mobile phone with SMS or WhatsApp capacity (can include the phone of a parent/caregiver if the participant is <18 years or does not have their own phone) Young people living without HIV from the same communities who meet all of the following criteria will be eligible for inclusion into this study: 1. Speak isiXhosa and or English, residing in the Khayelitsha / Mitchell's Plain area 2. 13-24 years (inclusive) 3. Willing and able to provide informed telephonic or in person consent 4. Has not previously tested positive for HIV and self-reports being HIV negative (i.e., not known to be living with HIV). 5. Regular access to a mobile phone (can include the phone of a parent/caregiver if the participant is <18 years or does not have their own phone) Exclusion Criteria: Young people living with HIV who meet any of the following criteria will be excluded from this study: 1. Not 13-24 years (inclusive) 2. Unwilling or unable to provide informed telephonic or in person consent 3. Not currently receiving ART care at a Desmond Tutu Health Foundation health facility 4. No regular access to a mobile phone with SMS or WhatsApp capacity 5. Planning to relocate in the next 6 months Young people living without HIV from the same communities who meet any of the following criteria will be excluded this study: 1. Not 13-24 years (inclusive) 2. Unwilling or unable to provide informed telephonic or in person consent 3. Previously tested positive for HIV or is known to be living with HIV 4. No regular access to a mobile phone 5. Planning to relocate in the next 6 months |
Country | Name | City | State |
---|---|---|---|
South Africa | Gugulethu Community Health Centre | Cape Town | Western Cape |
Lead Sponsor | Collaborator |
---|---|
Desmond Tutu HIV Foundation | Karolinska Institutet, University of KwaZulu, University of North Carolina, Chapel Hill, ViiV Healthcare |
South Africa,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Acceptability of a remote service delivery and mobile support intervention assessed by the number of participants opting in to receive courier delivery of ART. | Program evaluation of a remote service delivery including mobile support intervention and courier delivery of ART amongst young people living with HIV. | 6 months | |
Primary | Engagement in HIV care assessed by serial measurements of HIV Viral load. | Measurement of HIV viral load will be done at baseline, month three and month six to determine whether adherence to ART has been met (decrease or increase in HIV Viral load) | 6 months | |
Primary | Changes in Gender Based Violence (GBV) incidence as a result of COVID lock-down measures as assessed by self reported surveys. | Investigate changes in self-reported GBV experience or perpetration, and other individual, social-behavioral, and structural factors that have been impacted by COVID-19 lock down orders. | 6 months | |
Secondary | Incidence of COVID-19 infection by assessing participant IgG antibody levels. | Retrospective COVID-19 antibody testing at baseline and month | 6 months | |
Secondary | Qualitative themes assessed from in-depth individual interview data | Qualitative interviews will be used to inform intervention utility and the development of an intervention to reduce GBV | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |